Astrazeneca Ab

Zeneca Limited

Astra Zeneca U.k. Limited

Paul Turner

Johannes Wilhelmus Maria Nissink

Kevin Michael Foote

Michael J Smithers

John Preston

Andrew Stocker

John Wall Rayner

David Waterson

Jeffrey Philip Poyser

Justin Fairfield Bower

Jon James Gordon Winter

There is provided pyrimidinyl compounds of Formula (I), wherein: or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

Chemical compounds

Compounds of formula (I)Q-L-W&#x2014;C(&#x2550;X)&#x2014;Z&#x2014;Pwherein

Heterocyclic compounds as CCR2B antagonists

The invention relates to heterocyclic derivatives of formula (I)A&#x2014;B&#x2014;X&#x2014;T(R)&#x2014;L&#x2014;T(R)&#x2014;X&#x2014;Q&#x2003;&#x2003;(I)or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocyclic derivatives

The invention relates to heterocyclic derivatives of the formula (I): A&mdash;B&mdash;X,&mdash;T,(R,)&mdash;L,&mdash;T,(R,)&mdash;X,&mdash;Q or pharmaceutically acceptable salts thereof, which possess antithrombotic and anticoagulant properties due to their inhibition of Factor Xa and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect.

Heterocycle derivatives which inhibit factor Xa

Growing community of inventors

Macclesfield, United Kingdom

Paul Turner